Earnings call Advanced Enzymes' Q2 FY25 revenue declined 7% YoY to ₹1,461M due to export slowdown and ₹83M in deferred revenue. EBITDA margin dropped to 29%. Despite H1 softness, management expects ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Advanced Enzyme Technologies Ltd (BOM:540025) reports robust revenue and profit growth for Q2 FY26, despite facing tariff-related hurdles in the US market.

Total expenditure for the period under review added up to Rs 135.27 crore, up 19.2% YoY. This was primarily due to higher raw material costs (up 24.8% YoY), higher employee expenses (up 10.8% YoY) and ...

On August 8, Advanced Enzyme Technologies reveals figures for Q1. Wall Street analysts expect Advanced Enzyme Technologies will report earnings per share of INR 2.89. Watch Advanced Enzyme ...

DUBLIN, March 18, 2020 /PRNewswire/ -- The "Technical Enzymes Market by Type (Amylases, Cellulases, Proteases, and Lipases), Industry (Biofuel, Starch, Textiles ...

* Seeks members' nod to approve related party transaction with JC Biotech Private Limited‍ Source text: Further company coverage: Sign up here. Macro Matterscategory Fed's rate cut revives small ...

Earnings call Advanced Enzymes reported Q3 FY25 consolidated revenue of ₹1,691 million, up 5% YoY and 16% QoQ (adjusted growth 5%). EBITDA rose 3% YoY and 30% QoQ to ₹553 million, with margins at 33%.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.